Article title: “DCVax®-L—developed by Northwest Biotherapeutics”
Authors: Stavros Polyzoidis and Keyoumars Ashkan
Journal: Human Vaccines & Immunotherapeutics
Bibliometrics: Volume 10, Issue 11, pages 3139-3145
DOI: 10.4161/hv.29276
Conflicts of interests were not disclosed in the original article. The authors would like to make the following disclosure of potential conflicts of interest:
Dr Stavros Polyzoidis is a Fellow at the Department of Neurosurgery at King's College Hospital in London, United Kingdom. He is Sub-investigator in the Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM). Professor Keyoumars Ashkan is a Consultant Neurosurgeon at the Department of Neurosurgery at King's College Hospital in London, United Kingdom. He is Chief Investigator for Europe in the Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM).
The authors apologize for any inconvenience caused.